Duo Oncology Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.62M

  • Investors
  • 10

Duo Oncology General Information

Description

Developer of a clinical-stage biotechnology platform designed to replace traditional chemotherapy with more precise and tolerable cancer treatments. The company offers targeted, next-generation cancer therapies with reduced toxicity and improved selectivity, enabling patients with aggressive cancers to receive effective treatment with fewer debilitating side effects.

Contact Information

Website
www.duooncology.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4165 Blair Street
  • Pittsburgh, PA 15207
  • United States
+1 (412)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Nanotechnology, HealthTech, Oncology
Corporate Office
  • 4165 Blair Street
  • Pittsburgh, PA 15207
  • United States
+1 (412)

Duo Oncology Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Duo Oncology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 07-Aug-2026 $1.62M Completed Pre-Clinical Trials
7. Later Stage VC 11-Jul-2025 Completed Pre-Clinical Trials
6. Early Stage VC (Series A) Completed Pre-Clinical Trials
5. Accelerator/Incubator 21-Mar-2024 Completed Pre-Clinical Trials
4. Accelerator/Incubator Completed Pre-Clinical Trials
3. Grant 27-Oct-2023 Completed Pre-Clinical Trials
2. Seed Round 11-Aug-2023 $4.25M $4.25M Completed Pre-Clinical Trials
1. Accelerator/Incubator 03-Nov-2020 Completed Pre-Clinical Trials
To view Duo Oncology’s complete valuation and funding history, request access »

Duo Oncology Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed
Seed-1
To view Duo Oncology’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Duo Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a clinical-stage biotechnology platform designed to replace traditional chemotherapy with more precise and
Drug Discovery
Pittsburgh, PA
8 As of 2025

London, United Kingdom
 

Maastricht, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Duo Oncology Competitors (82)

One of Duo Oncology’s 82 competitors is Ellipses Pharma, a Venture Capital-Backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ellipses Pharma Venture Capital-Backed London, United Kingdom
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Genprex Formerly VC-backed Austin, TX
Altimmune Formerly VC-backed Gaithersburg, MD
You’re viewing 5 of 82 competitors. Get the full list »

Duo Oncology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Duo Oncology Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Cancer Institute I-Corps Accelerator/Incubator
U.S. Department of Health and Human Services Government
BeOne Medicines Corporation Minority
Innovation Works Venture Capital Minority
NuFund Venture Group Angel Group Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Duo Oncology FAQs

  • When was Duo Oncology founded?

    Duo Oncology was founded in 2020.

  • Where is Duo Oncology headquartered?

    Duo Oncology is headquartered in Pittsburgh, PA.

  • What is the size of Duo Oncology?

    Duo Oncology has 8 total employees.

  • What industry is Duo Oncology in?

    Duo Oncology’s primary industry is Drug Discovery.

  • Is Duo Oncology a private or public company?

    Duo Oncology is a Private company.

  • What is Duo Oncology’s current revenue?

    The current revenue for Duo Oncology is .

  • How much funding has Duo Oncology raised over time?

    Duo Oncology has raised $14.5M.

  • Who are Duo Oncology’s investors?

    National Cancer Institute I-Corps, U.S. Department of Health and Human Services, BeOne Medicines, Innovation Works, and NuFund Venture Group are 5 of 10 investors who have invested in Duo Oncology.

  • Who are Duo Oncology’s competitors?

    Ellipses Pharma, Cristal Therapeutics, Inovio Pharmaceuticals, Genprex, and Altimmune are some of the 82 competitors of Duo Oncology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process